Clay Siegall; A Proven Leader in The Biopharmaceutical Industry

The founder and current CEO of Seattle Genetic, Dr. Clay Siegall is a trained scientist specializing in targeted cancer therapies. His company specializes in research and development of Drugs to the treat types of cancer that have received little attention over the years. A holder of B.S in Zoology and Ph.D. in Genetics, he says he always had an interest in medicine and a desire to use the power of technology to overcome diseases. Though he admits that there are huge risks in running a biopharmaceutical industry, he accounts his love for work and different working habits as the pillars that have seen him through.

 

Before co-founding Seattle Genetics in 1998, Dr. Siegall first worked at the National Cancer Institute, National Institutes of Health between 1988 and 1991 and later as a leading researcher at Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. As the president of Seattle Genetic, Dr. Siegall has guided the company to be the world’s leader in the development of ADCs, antibody-Drug conjugates. In 2011 the FDA approved the company’s first ADC product, ADCETRIS®. Today, ADCETRIS is approved in at least 65 countries making it a global brand. Besides, there has been a continued advancement by Seattle Genetics in the diverse pipeline of proprietary ADCs for cancer treatment.

 

Seattle Genetic has under DR. Siegall’s leadership entered into numerous strategic ADC technology licenses. These technologies have to date generated an estimated income of $350 million. Through private and public funding, DR. Siegall has also guided Seattle Genetics to securing over $1.2 billion. His outstanding performance as a leader at Seattle Genetic has seen Dr. Siegall appointed as a director in various biopharmaceutical and biotechnology companies.

 

In 2014, he earned an appointment to the board of trustees at Ultragenyx Pharmaceutical where he gained recognition as a proven leader in the biopharmaceutical industry. At the time of the designation, Dr. Siegall was already a Director of Mirna Therapeutics and Alder Biopharmaceuticals. As an entrepreneur and a leader, Dr. Clay Siegall recommends entrepreneurs to be lifelong learners and collaborate with other successful industry leaders who will help in the manifestation of ideas and approaches.

 

Leave a Reply